Viridian Therapeutics Inc (VRDN)

$13.45 1.18 (8.07%)

16:00 EDT VRDN Stock Quote Delayed 30 Minutes

VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024

By InvestorPlace Earnings May 8, 2024

VRDN stock results show that Viridian Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

More Articles

Volume:

Previous Close -

Market Cap 128.95M

PE Ratio -3.00

EPS -4.49

Volume (Avg. Vol.) 1.11M

Day's Range $13.39 - $14.76

52-Week Range $10.93 - $28.35

Dividend & Yield N/A (N/A)

VRDN Stock Predictions, Articles, and Viridian Therapeutics Inc News

From InvestorPlace
From the Web

Viridian Therapeutics (VRDN) Stock Jumps 60% on Promising Clinical Trial

By Josh Enomoto, InvestorPlace Contributor Aug 15, 2022

Viridian Therapeutics is among the biggest winners on Monday as it released encouraging clinical data, thus skyrocketing VRDN stock.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Sep 22, 2021

Good morning, investor! We're halfway through the week and starting off Wednesday with a look at the biggest pre-market stock movers today.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Sep 21, 2021

Good morning, trader! Another busy day of trading is already underway as we look at the biggest pre-market stock movers for Tuesday!

Viridian Therapeutics stock slides on pricing stock offering to raise $150 million

From Seeking Alpha Jan 18, 2024

Viridian Therapeutics (VRDN) announces the pricing of an underwritten public offering with gross proceeds of approximately $150.0 million. The company is sellin

Viridian Therapeutics starts public offering of common and preferred stock (NASDAQ:VRDN)

From Seeking Alpha Jan 17, 2024

Viridian Therapeutics announces a public offering of common stock and Series B preferred stock to raise funds for clinical development programs.

Viridian Therapeutics files to sell 15.02M shares for holders (NASDAQ:VRDN)

From Seeking Alpha Nov 30, 2023

Viridian Therapeutics files a prospectus for the resale of 15.02M shares by selling stockholders, not an offer to sell these securities.

Viridian Therapeutics GAAP EPS of -$1.09 beats by $0.08, revenue of $0.07M misses by $0.03M (NASDAQ:VRDN)

From Seeking Alpha Nov 14, 2023

Viridian Therapeutics beats Q3 earnings expectations with a GAAP EPS of -$1.09, however, revenue misses by $0.03M.

Why Shares of Viridian Therapeutics Are Falling Tuesday

From The Motley Fool Jul 11, 2023

The company announced preliminary trial results for its lead therapy.

Viridian Therapeutics (VRDN) Gets a Buy from Oppenheimer

From TipRanks Dec 5, 2022

Oppenheimer analyst Leland Gershell reiterated a Buy rating on Viridian Therapeutics (VRDN – Research Report) on November 30 and set a price target...

ADVERTISEMENT